A debilitating mental illness, schizophrenia can be difficult to diagnose. Because physiological evidence confirming the disease can only be gathered from the brain during an autopsy, mental health professionals have had to rely on a battery of psychological evaluations to diagnose their patients.
[More]
The longer patients with first-episode psychosis go untreated, the less likely they are to achieve remission within a year of starting treatment, report researchers.
[More]
BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus.
[More]
As scientists probe and parse the genetic bases of what makes a human a human (or one human different from another), and vigorously push for greater use of whole genome sequencing, they find themselves increasingly threatened by the unthinkable: Too much data to make full sense of.
[More]
Researchers from Neuroscience Research Australia (NeuRA) have presented new results about the role of testosterone in schizophrenia at the International Congress on Schizophrenia Research being held in Orlando, Florida.
[More]
As scientists probe and parse the genetic bases of what makes a human a human (or one human different from another), and vigorously push for greater use of whole genome sequencing, they find themselves increasingly threatened by the unthinkable: Too much data to make full sense of.
[More]
Itchy eyes, scratchy throat, running nose--it's allergy season! What triggers these allergic reactions, and how do allergy medications work?
[More]
The current special issue of Technology and Innovation - Proceedings of the National Academy of Inventors, devoted to studies on medical technology and health care delivery, focuses on a wide range of topics, from new technologies to reduce the cost of health care to understanding the human microbiome.
[More]
A study shows that patients with schizophrenia struggle to recognize angry facial expressions, often mistaking them for fear.
[More]
UK researchers have found that despite being a major contributor to premature deaths among patients with schizophrenia, cardiovascular disease is less likely to be recorded on their primary care records than people without schizophrenia.
[More]
Cumulative genetic risk for schizophrenia has been linked to impaired prefrontal brain activity, in findings that support an additive genetic risk model for a polygenic phenotype.
[More]
The newly proposed scientific project to understand the most complicated 3 pounds of material in the world - the human brain - is the topic of an article in the current edition of Chemical & Engineering News, the weekly newsmagazine of the American Chemical Society, the world's largest scientific society.
[More]
Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.
[More]
Using spinning disk microscopy on barely day-old zebra fish embryos, University of Oregon scientists have gained a new window on how synapse-building components move to worksites in the central nervous system.
[More]
For the first time, human embryonic stem cells have been transformed into nerve cells that helped mice regain the ability to learn and remember.
[More]
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in the Phase 2b study of TC-5619 as a treatment for negative symptoms and cognitive dysfunction in schizophrenia.
[More]
An excess of the brain neurotransmitter glutamate may cause a transition to psychosis in people who are at risk for schizophrenia, reports a study from investigators at Columbia University Medical Center published in the current issue of Neuron.
[More]
The Korea-based international pharmaceutical company, SK Biopharmaceuticals, announced today the U.S. Food and Drug Administration has authorized the Investigational New Drug application for SKL15508 to treat cognitive impairment associated with schizophrenia.
[More]
Overworked and stressed out? Look on the bright side. Some stress is good for you. "You always think about stress as a really bad thing, but it's not," said Daniela Kaufer, associate professor of integrative biology at the University of California, Berkeley.
[More]
BioLineRx, a biopharmaceutical development company, announced today positive Phase IIa results for BL-7040, an orally available drug for treating inflammatory bowel disease.
[More]